RT Journal Article
SR Electronic
T1 Detection of a BA.1/BA.2 recombinant in travelers arriving in Hong Kong, February 2022
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.28.22273020
DO 10.1101/2022.03.28.22273020
A1 Gu, Haogao
A1 Ng, Daisy YM
A1 Liu, Gigi YZ
A1 Cheng, Samuel SM
A1 Krishnan, Pavithra
A1 Chang, Lydia DJ
A1 Cheuk, Sammi SY
A1 Hui, Mani MY
A1 Lam, Tommy TY
A1 Peiris, Malik
A1 Poon, Leo
YR 2022
UL http://medrxiv.org/content/early/2022/04/02/2022.03.28.22273020.abstract
AB We studied SARS-CoV-2 genomes from travelers arriving in Hong Kong from November-2021 to February-2022. Apart from detecting Omicron (BA.1, BA1.1. and BA.2) and Delta variants, we detected a BA.1/BA.2 recombinant in two epidemiologically linked cases. This recombinant has a breakpoint near the 5’ end of Spike gene (nucleotide position 20055-21618).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by Research Grants Council of Hong Kong theme-based research schemes (T11-705/21-N) and the Health and Medical Research Fund (COVID190205).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB at the University of Hong Kong gave ethical approval for this work (IRB number: UW 20-168).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll deduced sequences can be available from GISAID. The GISAID accession number of our sequences are available online at: https://github.com/Leo-Poon-Lab/BA1_BA2_recombinant_HK/blob/main/GISAID_accessions.txt